The rapid evolution of CAR-T therapy is driving new strategies to improve targeting, delivery, and preclinical translation. Among these, in vivo CAR-T approaches—including lentiviral vectors and targeted lipid nanoparticles—offer the potential to generate CAR-T cells directly within the body, enabling more scalable and accessible cancer immunotherapies.
This webinar will explore how Biocytogen integrates fully human antibody discovery with translational mouse models to support conventional and in vivo CAR-T development. Biocytogen’s RenNano® platform generates diverse, fully human VHHs against T-cell markers such as CD5, CD7, and CD8. Their small size, strong tissue penetration, and ability to recognize inaccessible epitopes make them well suited for targeted delivery systems and next-generation CAR designs.
We will also introduce Biocytogen’s target-humanized and immune-reconstituted models, combined with relevant tumor models, for evaluating biodistribution, CAR-T expansion, immune-cell dynamics, safety, and antitumor efficacy. Selected studies will demonstrate applications of PBMC- and HSC-reconstituted models, longitudinal tumor monitoring, flow cytometry-based immune profiling, and other relevant readouts.
Join us to discover how our integrated antibody discovery and preclinical model platforms support CAR-T programs from early discovery through translational evaluation.
What you will learn:
Speaker:
Yanan Guo, Ph.D., Vice President of the Institute for Biologics
Zhongxiao Cong, Ph.D., Product Manager of Pharmacology Department
Panelist:
Yujie Liu, Ph.D., Head of Pharmacology Department
